Dr. Reddy’s Laboratories has seen its market valuation take a sharp hit, shedding 9% over the past two sessions. The sell-off was triggered by the company's decision to delay commercial shipments of its semaglutide product, citing technical complications regarding Active Pharmaceutical Ingredient (API) quality standards.
The disruption has forced several major brokerages to recalibrate their expectations. By trimming target prices and lowering earnings projections, analysts are signaling a period of near-term uncertainty as the firm works to resolve these production hurdles.
Despite the current volatility, institutional sentiment remains mixed but cautiously optimistic about the company's long-term trajectory. Analysts point to a robust pipeline, though they warn that the path to full-scale commercialization may be slower than previously anticipated.
Investors are now closely monitoring management's commentary for updates on production timelines. Whether the pharmaceutical giant can regain momentum depends largely on how swiftly it addresses these manufacturing concerns and stabilizes its supply chain efficiency.
